Spero Therapeutics Crescita futura
Criteri Future verificati 0/6
L'EPS di Spero Therapeutics dovrebbe crescere di 47.6% all'anno.
Informazioni chiave
n/a
Tasso di crescita degli utili
47.61%
Tasso di crescita dell'EPS
| Biotechs crescita degli utili | 25.5% |
| Tasso di crescita dei ricavi | n/a |
| Rendimento futuro del capitale proprio | n/a |
| Copertura analitica | None |
| Ultimo aggiornamento | n/a |
Aggiornamenti recenti sulla crescita futura
Recent updates
Spero Therapeutics: Tebipenem's FDA Path Supports A Speculative Buy
Summary Spero Therapeutics' lead asset is an oral carbapenem tebipenem for cUTI. This asset achieved Phase 3 noninferiority. In fact, this data supports GSK’s NDA resubmission strategy. The prior FDA setback from ADAPT-PO was addressed through PIVOT-PO. The new PIVOT-PO trial was actually stopped early after strong interim efficacy results. So, I believe their data is quite favorable this time. Also, SPRO’s partnership economics are meaningful. They can soon receive sizable resubmission milestone payments and royalties tied to commercialization. In my view, SPRO’s current valuation seems too low relative to the TAM they can unlock with tebipenem. So, I rate them a speculative 'Buy' at these levels. Read the full article on Seeking AlphaSpero Therapeutics, Inc. (NASDAQ:SPRO) Held Back By Insufficient Growth Even After Shares Climb 26%
Spero Therapeutics, Inc. ( NASDAQ:SPRO ) shareholders would be excited to see that the share price has had a great...
Positive Phase III Efficacy Will Unlock Expanded Antibiotic Markets
The downward revision in Spero Therapeutics’ consensus price target largely reflects declines in its future P/E multiple and net profit margin, resulting in a lower fair value estimate of $4.00. What's in the News The phase III PIVOT-PO trial of tebipenem HBr, an investigational oral treatment for complicated urinary tract infections (cUTIs), was stopped early due to efficacy, following an Independent Data Monitoring Committee recommendation.Is Spero Therapeutics (NASDAQ:SPRO) In A Good Position To Deliver On Growth Plans?
NasdaqGS:SPRO 1 Year Share Price vs Fair Value Explore Spero Therapeutics's Fair Values from the Community and select...Insufficient Growth At Spero Therapeutics, Inc. (NASDAQ:SPRO) Hampers Share Price
With a price-to-sales (or "P/S") ratio of 3.1x Spero Therapeutics, Inc. ( NASDAQ:SPRO ) may be sending very bullish...
Successful Phase III Trial Will Redefine Treatment For Complicated UTIs
Successful PIVOT-PO trial and regulatory approval could propel revenue growth, leveraging a strategic partnership with GSK for commercialization.Spero Therapeutics, Inc. (NASDAQ:SPRO) Looks Inexpensive After Falling 27% But Perhaps Not Attractive Enough
To the annoyance of some shareholders, Spero Therapeutics, Inc. ( NASDAQ:SPRO ) shares are down a considerable 27% in...Spero Therapeutics: Undervalued Based On Just Tebipenem And GSK Deal
Summary Spero Therapeutics' tebipenem, an oral carbapenem for cUTIs, has high approval potential, supported by a successful phase 3 trial and a GSK licensing deal. The need for oral carbapenems is critical due to rising resistance to current oral treatments for complicated urinary tract infections. Tebipenem's success in the confirmatory phase 3 trial is highly probable, given its prior phase 3 success and publication in NEJM. Despite risks, SPRO's valuation is attractive, with significant upside potential from tebipenem milestones and possible pipeline progress. Read the full article on Seeking AlphaThere Is A Reason Spero Therapeutics, Inc.'s (NASDAQ:SPRO) Price Is Undemanding
Spero Therapeutics, Inc.'s ( NASDAQ:SPRO ) price-to-sales (or "P/S") ratio of 0.5x might make it look like a strong buy...Insufficient Growth At Spero Therapeutics, Inc. (NASDAQ:SPRO) Hampers Share Price
Spero Therapeutics, Inc.'s ( NASDAQ:SPRO ) price-to-sales (or "P/S") ratio of 0.7x might make it look like a strong buy...Spero Therapeutics Delivers On Game Plan To Create Shareholder Value
Summary Spero Therapeutics, Inc. has continued to build and advance its pipeline over the past several months and is now on the verge of generating landmark data with multi-bagger potential. Spero has excellent downside protection and additional upside from the payments from the Tebipenem HBr deal with GSK. Spero's significant undervaluation and potential path forward are highlighted in the peer comparison. Read the full article on Seeking AlphaSpero Therapeutics, Inc. (NASDAQ:SPRO) Held Back By Insufficient Growth Even After Shares Climb 27%
Spero Therapeutics, Inc. ( NASDAQ:SPRO ) shares have continued their recent momentum with a 27% gain in the last month...Spero Therapeutics, Inc.'s (NASDAQ:SPRO) Share Price Boosted 26% But Its Business Prospects Need A Lift Too
The Spero Therapeutics, Inc. ( NASDAQ:SPRO ) share price has done very well over the last month, posting an excellent...Need To Know: Analysts Just Made A Substantial Cut To Their Spero Therapeutics, Inc. (NASDAQ:SPRO) Estimates
Today is shaping up negative for Spero Therapeutics, Inc. ( NASDAQ:SPRO ) shareholders, with the analysts delivering a...Spero Therapeutics, Inc. (NASDAQ:SPRO) Shares Fly 26% But Investors Aren't Buying For Growth
Those holding Spero Therapeutics, Inc. ( NASDAQ:SPRO ) shares would be relieved that the share price has rebounded 26...Industry Analysts Just Upgraded Their Spero Therapeutics, Inc. (NASDAQ:SPRO) Revenue Forecasts By 40%
Spero Therapeutics, Inc. ( NASDAQ:SPRO ) shareholders will have a reason to smile today, with the analysts making...We Think Spero Therapeutics (NASDAQ:SPRO) Can Easily Afford To Drive Business Growth
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...Previsioni di crescita degli utili e dei ricavi
| Data | Ricavi | Utili | Flusso di cassa libero | Liquidità dell'operazione | Avg. Numero di analisti |
|---|---|---|---|---|---|
| 3/31/2026 | 61 | 15 | 7 | 7 | N/A |
| 12/31/2025 | 67 | 9 | -13 | -13 | N/A |
| 9/30/2025 | 41 | -44 | -28 | -28 | N/A |
| 6/30/2025 | 49 | -54 | -32 | -32 | N/A |
| 3/31/2025 | 45 | -70 | -33 | -33 | N/A |
| 12/31/2024 | 48 | -69 | -23 | -23 | N/A |
| 9/30/2024 | 106 | 4 | -18 | -18 | N/A |
| 6/30/2024 | 118 | 17 | -14 | -14 | N/A |
| 3/31/2024 | 111 | 23 | -14 | -14 | N/A |
| 12/31/2023 | 104 | 23 | -33 | -33 | N/A |
| 9/30/2023 | 78 | -2 | 29 | 29 | N/A |
| 6/30/2023 | 54 | -10 | 12 | 12 | N/A |
| 3/31/2023 | 54 | -27 | 8 | 8 | N/A |
| 12/31/2022 | 54 | -46 | -8 | -8 | N/A |
| 9/30/2022 | 9 | -102 | -80 | -80 | N/A |
| 6/30/2022 | 10 | -113 | -84 | -84 | N/A |
| 3/31/2022 | 13 | -103 | -77 | -77 | N/A |
| 12/31/2021 | 18 | -90 | -64 | -64 | N/A |
| 9/30/2021 | 17 | -79 | -53 | -53 | N/A |
| 6/30/2021 | 18 | -76 | -70 | -70 | N/A |
| 3/31/2021 | 15 | -74 | -78 | -78 | N/A |
| 12/31/2020 | 9 | -79 | -86 | -86 | N/A |
| 9/30/2020 | 11 | -85 | -87 | -87 | N/A |
| 6/30/2020 | 12 | -84 | -75 | -75 | N/A |
| 3/31/2020 | 12 | -80 | -63 | -62 | N/A |
| 12/31/2019 | 18 | -61 | N/A | -50 | N/A |
| 9/30/2019 | 16 | -47 | N/A | -46 | N/A |
| 6/30/2019 | 12 | -39 | N/A | -42 | N/A |
| 3/31/2019 | 11 | -36 | N/A | -39 | N/A |
| 12/31/2018 | 4 | -42 | N/A | -40 | N/A |
| 9/30/2018 | 3 | -46 | N/A | -39 | N/A |
| 6/30/2018 | 3 | -47 | N/A | -44 | N/A |
| 3/31/2018 | 3 | -50 | N/A | -44 | N/A |
| 12/31/2017 | 2 | -46 | N/A | -39 | N/A |
| 9/30/2017 | 1 | -40 | N/A | -36 | N/A |
| 6/30/2017 | 1 | -35 | N/A | -32 | N/A |
| 3/31/2017 | 0 | -30 | N/A | -29 | N/A |
| 12/31/2016 | 0 | -30 | N/A | -29 | N/A |
Previsioni di crescita futura degli analisti
Guadagni vs tasso di risparmio: Dati insufficienti per determinare se la crescita degli utili prevista SPRO è superiore al tasso di risparmio ( 3.5% ).
Guadagni vs Mercato: Dati insufficienti per determinare se si prevede che gli utili di SPRO cresceranno più velocemente del mercato US
Guadagni ad alta crescita: Dati insufficienti per determinare se si prevede che gli utili di SPRO cresceranno in modo significativo nei prossimi 3 anni.
Ricavi vs Mercato: Dati insufficienti per determinare se si prevede che i ricavi di SPRO cresceranno più rapidamente del mercato US.
Ricavi ad alta crescita: Dati insufficienti per determinare se si prevede che i ricavi di SPRO cresceranno più rapidamente di 20% all'anno.
Previsioni di crescita dell'utile per azione
Rendimento futuro del capitale proprio
ROE futuro: Dati insufficienti per determinare se il Return on Equity di SPRO è previsto essere elevato tra 3 anni
Scoprire le aziende in crescita
Analisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/05/20 03:08 |
| Prezzo dell'azione a fine giornata | 2026/05/20 00:00 |
| Utili | 2026/03/31 |
| Utili annuali | 2025/12/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
Spero Therapeutics, Inc. è coperta da 6 analisti. 0 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| Esther Lannie Hong | Berenberg |
| Jason Matthew Gerberry | BofA Global Research |
| Esther Lannie Hong | Brean Capital Historical (Janney Montgomery) |